GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Cyclically Adjusted Book per Share

Lexaria Bioscience (Lexaria Bioscience) Cyclically Adjusted Book per Share : $1.28 (As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lexaria Bioscience's adjusted book value per share for the three months ended in Feb. 2024 was $0.526. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.28 for the trailing ten years ended in Feb. 2024.

During the past 12 months, Lexaria Bioscience's average Cyclically Adjusted Book Growth Rate was -22.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -13.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -16.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lexaria Bioscience was -13.10% per year. The lowest was -24.60% per year. And the median was -19.10% per year.

As of today (2024-05-21), Lexaria Bioscience's current stock price is $2.99. Lexaria Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2024 was $1.28. Lexaria Bioscience's Cyclically Adjusted PB Ratio of today is 2.34.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lexaria Bioscience was 16.10. The lowest was 0.37. And the median was 2.47.


Lexaria Bioscience Cyclically Adjusted Book per Share Historical Data

The historical data trend for Lexaria Bioscience's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Cyclically Adjusted Book per Share Chart

Lexaria Bioscience Annual Data
Trend Oct13 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.77 2.26 2.02 1.82 1.47

Lexaria Bioscience Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 1.57 1.47 1.37 1.28

Competitive Comparison of Lexaria Bioscience's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Lexaria Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Cyclically Adjusted PB Ratio falls into.



Lexaria Bioscience Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lexaria Bioscience's adjusted Book Value per Share data for the three months ended in Feb. 2024 was:

Adj_Book= Book Value per Share /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=0.526/125.4675*125.4675
=0.526

Current CPI (Feb. 2024) = 125.4675.

Lexaria Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201404 3.198 98.920 4.056
201407 2.950 99.315 3.727
201411 1.121 99.078 1.420
201502 0.900 99.078 1.140
201505 0.792 100.263 0.991
201508 0.528 100.579 0.659
201511 0.317 100.421 0.396
201602 0.178 100.421 0.222
201605 0.080 101.765 0.099
201608 0.156 101.686 0.192
201611 0.440 101.607 0.543
201702 0.368 102.476 0.451
201705 1.472 103.108 1.791
201708 1.327 103.108 1.615
201711 1.038 103.740 1.255
201802 1.170 104.688 1.402
201805 1.093 105.399 1.301
201808 0.948 106.031 1.122
201811 1.328 105.478 1.580
201902 1.069 106.268 1.262
201905 1.216 107.927 1.414
201908 0.907 108.085 1.053
201911 0.940 107.769 1.094
202002 0.699 108.559 0.808
202005 1.067 107.532 1.245
202008 0.841 108.243 0.975
202011 0.626 108.796 0.722
202102 2.306 109.745 2.636
202105 2.027 111.404 2.283
202108 2.317 112.668 2.580
202111 2.040 113.932 2.247
202202 1.925 115.986 2.082
202205 1.543 120.016 1.613
202208 1.336 120.569 1.390
202211 1.052 121.675 1.085
202302 0.836 122.070 0.859
202305 0.543 124.045 0.549
202308 0.376 125.389 0.376
202311 0.363 125.468 0.363
202402 0.526 125.468 0.526

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Lexaria Bioscience  (NAS:LEXX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lexaria Bioscience's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.99/1.28
=2.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lexaria Bioscience was 16.10. The lowest was 0.37. And the median was 2.47.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lexaria Bioscience Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry
Traded in Other Exchanges
N/A
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Executives
Catherine C. Turkel director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey officer: Chief Financial Officer 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka director, 10 percent owner, officer: CEO 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle officer: Secretary 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr director
Brian W. Quigley director 100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie director 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger officer: CFO 8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty director, 10 percent owner 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar director, officer: CFO 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter director 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford director 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke officer: Sr. VP, Business Development 38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini director, 10 percent owner 11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan director, officer: Vice President - Corp Develop SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6